Hilmar Bading MD

Hilmar Bading studied medicine at Heidelberg University, obtained his doctorate at the Max-Planck-Institute for Medical Research (Heidelberg), was a post-doc at the Max-Planck-Institute for Molecular Genetics (Berlin) and at Harvard Medical School (Boston), and Group Leader at the MRC Laboratory of Molecular Biology (Cambridge, England).

Since 2001, he has been Director of the Institute of Neurobiology and of the Interdisciplinary Center for Neuroscience at Heidelberg University. He discovered toxic extrasynaptic NMDA receptor signaling and neuroprotective NMDAR/TRPM4 interface inhibitors. He is a grantee of the European Research Council, a member of the German National Academy of Science Leopoldina, and founder of FundaMental Pharma and the Foundation BrainAid.